FKBP4 and neoplasm: This highlights the complex, and sometimes opposing, roles of FKBP51 inhibition in different pathological contexts, underscoring the importance of thoroughly evaluating the tumor immune microenvironment when developing FKBP51-targeted therapies, especially for cancers.